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OBJECTIVES: In the Anglo-Scandinavian Outcomes Trial
(ASCOT), patients with normal or mildly elevated cholesterol
and treated hypertension, treated with atorvastatin 10mg had
36% fewer fatal coronary events and non-fatal heart attacks, a
27% reduction in fatal and non-fatal stroke, and a 21% reduc-
tion in CV events and procedures The objective of this study was
to evaluate the cost-effectiveness of this strategy. METHODS:
Analyses were based on cost per event avoided. Cardiovascular
events and procedures and number of non-fatal myocardial
infarctions (MI) and cardiovascular deaths were the measures of
effectiveness. Costs for resources (study drug, concomitant 
medications, hospitalization, ambulatory visits) were estimated
based on data collected on the case report forms, and local costs
for Sweden and the UK. Data from the intention to treat popu-
lation was aggregated. Prices in 2003, Using Euros, were (1€ =
9.1627 SEK, 0.6285 GBP). RESULTS: The net cost per-patient
in Sweden was 450€ (total cost of 4201€ vs 3751€ in the placebo
arm) and 410€ in the UK (5528€ compared to 5118€). Cost for
the study drug was 1034€ and 1087€ in Sweden and the UK
respectively. Part of this cost is offset by saving in other
resources, mainly hospitalizations. Cost-effectiveness ratios are
12,758€ and 38,727€ per event avoided in Sweden for total car-
diovascular events and procedures and for non-fatal MI and
death from coronary heart disease respectively and 11,628€ and
35,298€ per event avoided for the two different endpoints in the
UK. Atorvastatin was thus more expensive than placebo but also
more effective. CONCLUSION: Based on comparisons with
other studies on lipid-lowering we conclude that treatment as 
in the ASCOT study, with atorvastatin 10mg appears to be a
cost-effective treatment strategy.
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OBJECTIVES: To evaluate the cost-effectiveness of N-terminal
pro-Brain natriuretic peptide (NT-proBNP) in the diagnostic
assessment of patients with dyspnea in the Emergency Depart-
ment (ED). METHODS: We developed a decision model to
compare standard clinical assessment versus patient evaluation
guided by NT-proBNP (Elecsys proBNP assay, Roche Diagnos-
tics). The model represents diagnostic accuracy for acute con-
gestive heart failure (CHF) of both strategies and resulting events
during the initial ED visit and 60-day follow-up. Clinical data
were based on the PRIDE Study. In this prospective study of 599
patients presenting to the ED with dyspnea, an NT-proBNP >
900pg/ml was the strongest predictor of ﬁnal diagnosis of acute
CHF, as judged by blinded physicians. The primary clinical end-
point of our cost-effectiveness analysis was serious adverse
events (SAE) including urgent care visits, ED presentations, hos-
pitalizations, and deaths. Secondary endpoints were accuracy of
CHF diagnosis and 60-day mortality. Our model assumes that
resource utilization depends on true CHF status and probability
of CHF as estimated by ED physicians, thus, the economic 
endpoint was reduction in direct medical costs due to saved
echocardiograms and hospitalizations. Costs were based on the
MGH cost accounting database, Transition Systems Inc. (TSI).
RESULTS: Diagnostic assessment and management with NT-
proBNP was associated with a 10% reduction in direct medical
costs, a cost savings of $492 per patient, and a 2.5% relative
risk reduction of SAE. NT-proBNP testing dominated standard
assessment. Furthermore, NT-proBNP testing was associated
with a 1.2% reduction in 60-day mortality, in spite of a 1%
reduction in overall diagnostic accuracy. NT-proBNP testing
reduced echocardiograms by 58%, prevented 13% of initial 
hospitalizations and reduced hospital days by 12%. CONCLU-
SIONS: The use of NT-proBNP in the diagnostic assessment of
acute CHF improves patient outcomes and leads to potential
cost-savings of more than $500 million in the US health care
system.
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OBJECTIVES: The use of warfarin has become prevalent par-
ticularly for preventing stroke in non-valvular atrial ﬁbrillation
in older people. Any increase in the number of adverse drug reac-
tions (ADRs) in actual practice could have important implica-
tions for costs of care. There is a paucity of data on the cost
consequences of warfarin related ADRs. METHODS: The inci-
dence of ADRs was examined in an inception cohort of 735
patients in Tayside accumulating 583 patient years follow-up,
who were ﬁrst dispensed warfarin for any indication between
July 2000 and December 2000. Inpatient acute care costs for the
National Health Service were calculated for major bleeding, as
deﬁned by Landefeld (1989), other minor events and asympto-
matic over-anticoagulation (admission to hospital for manage-
ment of INR > 4.4). Costs were derived from the Scottish Health
Service Costs Manual 2001/02 and were based on length of stay
in speciﬁc specialties and hospitals. The base case calculated
mean direct costs per period of care. The bootstrap method was
used to calculate the mean and 95% conﬁdence interval cost per
admission to hospital for ADR based on direct costs alone.
RESULTS: The incidence rate of major bleeding was 1.8%/year
(95% CI 0.7%–2.9%). There were also 29 minor hospitalisable
events and 13 admissions for over-anticoagulation. The mean
acute direct in-patient care cost for a major bleed was £1488
(95% CI £626–£2350), and for a minor bleed £345 (95% CI
£239–£450). Costs associated with over-anticoagulation were
£514 (95% CI £179–£848). The bootstrap mean admission cost
based on direct costs was £627 (95% CI £171–£1294). Half of
the total cost of £33,036 (and 214 in-patient days of care) could
be attributed to minor events and over-anticoagulation manage-
ment. CONCLUSIONS: From a direct cost of care perspective
minimising admissions for “minor” events could result in 
signiﬁcant savings.
